{"id":21471,"date":"2023-07-05T07:56:09","date_gmt":"2023-07-05T11:56:09","guid":{"rendered":"https:\/\/medicarereport.org\/?p=21471"},"modified":"2023-07-05T07:56:10","modified_gmt":"2023-07-05T11:56:10","slug":"patients-squeezed-in-fight-over-who-gets-to-bill-for-pricey-infusion-drugs","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=21471","title":{"rendered":"Patients Squeezed in Fight Over Who Gets to Bill for Pricey Infusion Drugs"},"content":{"rendered":"\n

(By Samantha Liss for KFF Health News)<\/p>\n\n\n\n

Health insurers and medical providers are battling over who should supply high-cost infusion drugs for patients, with the tussle over profits now spilling into statehouses across the country.<\/p>\n\n\n\n

The issue is that some insurers are bypassing hospital pharmacies and physician offices and instead sending more complex drugs through third-party pharmacies. Those pharmacies then send the medications directly to the medical provider or facility for outpatient infusing, which is called \u201cwhite bagging,\u201d or, more rarely, to patients, in what is called \u201cbrown bagging.\u201d That shifts who gets to buy and bill for these complex medications, including pricey chemotherapy drugs. Continue reading here…<\/a><\/p>\n\n\n\n

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF \u2014 the independent source for health policy research, polling, and journalism<\/p>\n\n\n\n

\"\"<\/p>\n\n\n\n

Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/p>\n","protected":false},"excerpt":{"rendered":"

(By Samantha Liss for KFF Health News) Health insurers and medical providers are battling over who should supply high-cost infusion<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,20,15],"tags":[749,503,238,747,750,748],"class_list":["post-21471","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-health-care-redesign","category-part-dprescription-drugs","tag-brown-bagging","tag-health-insurance-companies","tag-healthcare-finance","tag-infusion-drugs","tag-third-party-pharmacies","tag-white-bagging"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/21471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21471"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/21471\/revisions"}],"predecessor-version":[{"id":21472,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/21471\/revisions\/21472"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}